EUDA Health Holdings Ltd 6-K, filed Dec 5, 2025
EUDA Health Holdings Ltd (EUDA)
About this 6-K
EUDA Health Holdings Ltd filed this 6-K on December 5, 2025.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of December 2025
Commission File Number: 001-40678
EUDA Health Holdings Limited
(Exact Name of Registrant as Specified in its Charter)
60 Kaki Bukit Place, #03-01 Eunos Techpark, Singapore 415979
(Address of Principal Executive Offices and Zip Code)
Registrant’s telephone number, including area code: +65 6327 1110
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐
Other Events.
On December 5, 2025, EUDA Health Holdings Limited issued the press release filed herewith as Exhibit 99.1.
Exhibits
| 99.1 | Press release dated December 5, 2025. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| Dated: December 5, 2025 | ||
| EUDA Health Holdings Limited | ||
| /s/ Alfred Lim | ||
| By: | Alfred Lim | |
| Chief Executive Officer | ||
Exhibit 99.1
EUDA Health Holdings Limited Announces Execution of Securities Purchase Agreement
SINGAPORE, Dec. 05, 2025 (GLOBE NEWSWIRE) — EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or “the Company”), a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that it entered into a securities purchase agreement on November 26, 2025 with Streeterville Capital, LLC, a Utah limited liability company, for the sale of a convertible warrant (the “Warrant”) for an aggregate purchase price of US$100,000. The Warrant is exercisable for up to 2,000,000 newly issued EUDA ordinary shares (the “Warrant Shares”) at an exercise price of US$6.00 per share and is being offered pursuant to the Company’s effective shelf registration statement on Form F-3 (File No. 333-282723) and a related prospectus supplement.
Streeterville Capital is an investment firm with operations in Utah and Tennessee with investments in companies including Cingulate, the Marygold Companies and Damon Inc.
The Warrant may be exercised for cash for ninety (90) days from the date of issuance, subject to extension by mutual agreement between the Company and Streeterville Capital (the “Cash Exercise Period”). During the Cash Exercise Period, the Warrant may only be exercised for cash, and the Company will have the right to require Streeterville Capital to exercise the Warrant, up to 10% of the cumulative dollar trading volume during a measurement period, if (i) the closing price of the Company’s ordinary shares on Nasdaq is at or above US$7.50 for five (5) consecutive trading days and (ii) the cumulative trading dollar volume over that period is at least US$1,500,000.
Mr. Alfred Lim, CEO of EUDA, commented, “This agreement represents another deliberate step in strengthening our capital position and advancing EUDA’s growth strategy. The warrant financing gives us the flexibility to deploy capital into high-return initiatives – including new centers, partnerships and technology – as we broaden our footprint across Asia’s fast-growing non-invasive healthcare market. By combining prudent financing with disciplined execution, we aim to accelerate the expansion of our healthcare ecosystem while creating long-term value for our patients, partners and shareholders.”
About EUDA Health Holdings Limited
EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based leading non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which is experiencing significant demographic shifts as more than 30% of the population ages rapidly. By offering innovative, accessible, and science-backed health solutions, EUDA is positioned to lead the transformation of regional healthcare from reactive medical treatment to proactive, longevity-focused care. EUDA also runs a Singapore-based property management business.
Forward-Looking Statements
This document may contain forward-looking statements regarding risks and uncertainties. These statements usually use forward-looking words, such as the words “estimates,” “projected,” “expects,” “envisions,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions). These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside EUDA’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. You should not overly rely on forward-looking statements that are only applicable to the date of publication of this document. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.